| Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287) |
|---|
| 02/06/2003 | CA2857312A1 Nucleic acids, polypeptides, and methods for modulating apoptosis using deoxyhypusine synthase (dhs) |
| 02/06/2003 | CA2455726A1 Treatment of muscular dystrophy with cord blood cells |
| 02/06/2003 | CA2454822A1 Nucleic acids, polypeptides, and methods for modulating apoptosis using apoptosis-specific eif-5a |
| 02/06/2003 | CA2452159A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods |
| 02/05/2003 | EP1280909A2 Human lipocalin homologs and polynucleotides encoding the same |
| 02/05/2003 | EP1280820A2 Anti-inflammatory compounds and uses thereof |
| 02/05/2003 | EP1280806A1 THIENO 2,3-d]PYRIMIDINEDIONES AND THEIR USE AS PHARMACEUTICALS |
| 02/05/2003 | EP1280777A1 Tetrahydroisoquinoline analogs useful as growth hormone secretagogues |
| 02/05/2003 | EP1280572A1 Delivery devices for treatment of vascular disease |
| 02/05/2003 | EP1280570A2 Delivery devices for treatment of vascular disease |
| 02/05/2003 | EP1280569A1 Delivery systems for treatment of vascular disease |
| 02/05/2003 | EP1280568A1 Delivery devices for treatment of vascular disease |
| 02/05/2003 | EP1280546A1 Method and composition for the treatment of angiogenesis |
| 02/05/2003 | EP1280530A1 Treatment of fibromyalgia and chronic fatigue syndrome |
| 02/05/2003 | EP1280515A2 Pharmaceutical compositions comprising cannabis |
| 02/05/2003 | EP1280512A2 Delivery systems for treatment of vascular disease |
| 02/05/2003 | CN1394621A Medicine for external application for curing traumatic injury |
| 02/04/2003 | US6515002 Compounds and compositions for treating C1s-mediated diseases and conditions |
| 02/04/2003 | US6514983 Inhibitors of the nucleic enzyme poly(adenosine 5'-diphospho-ribose)polymerase |
| 02/04/2003 | US6514973 Treatment of transmethylation disorders comprising one or more compounds selected from phosphatidyl serines, methyl transporters, and methyl and methylene donors with exipient |
| 02/04/2003 | US6514970 Urotensin-II receptor antagonists |
| 02/04/2003 | US6514960 Use of bismuth subgallate in inhibition of production of nitric oxide synthase |
| 02/04/2003 | US6514756 Human myoblast cell lines and their uses |
| 01/30/2003 | WO2003008574A1 Mutations in ion channels |
| 01/30/2003 | WO2003008448A2 Novel human proton-gated channels |
| 01/30/2003 | WO2003008444A2 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 01/30/2003 | WO2003008443A2 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 01/30/2003 | WO2003008411A1 Substituted piperazine compounds and their use as fatty acid oxidation inhibitors |
| 01/30/2003 | WO2003008410A2 Polypyrroles as agents for treating cancer, treating viral diseases and causing immunosuppression |
| 01/30/2003 | WO2003008407A2 Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use |
| 01/30/2003 | WO2003008398A1 Aryl substituted thiazolidinones and the use thereof |
| 01/30/2003 | WO2003008371A1 Substituted 4-aminocyclohexanol derivatives |
| 01/30/2003 | WO2003008370A1 Substituted 4-aminocyclohexanols |
| 01/30/2003 | WO2003007993A1 Combination of an aldosterone receptor antagonist and an hmg coa reductase inhibitor |
| 01/30/2003 | WO2003007990A1 Myosin agonist |
| 01/30/2003 | WO2003007978A1 Alpha-fetoprotein peptides and uses thereof |
| 01/30/2003 | WO2003007973A1 Use of ginkgo biloba extracts for preparing a medicine for treating sarcopenia |
| 01/30/2003 | WO2003007972A1 Agent for the external treatment of pain and skin disorders |
| 01/30/2003 | WO2003007887A2 Substituted imidazoles as cannabinoid receptor modulators |
| 01/30/2003 | WO2002088079A3 Dual inhibitors of pde 7 and pde 4 |
| 01/30/2003 | WO2002070510A3 Amino dicarboxylic acid derivatives with pharmaceutical properties |
| 01/30/2003 | WO2002034243A3 Method for the treatment of neurological and neuropsychological disorders |
| 01/30/2003 | WO2002034242A3 Method for the treatment of neurological and neuropsychological disorders |
| 01/30/2003 | WO2002014536A3 Odulating multiple lineage kinase proteins |
| 01/30/2003 | WO2002002634A3 Human extracellular matrix and cell adhesion polypeptides |
| 01/30/2003 | WO2001091771A3 Compositions for treating back and leg discomfort containing herbals and/or nutritional supplements and/or minerals and/or vitamins |
| 01/30/2003 | US20030023990 Jnk3 modulators and methods of use |
| 01/30/2003 | US20030022915 Treating obsessive-compulsive disorder, acute stress disorder, post traumatic stress disorder, social anxiety disorder, somatization disorder, specific social phobia, premenstrual dysphoric disorder, and other psychological disorders |
| 01/30/2003 | US20030022907 Anxiolytic agents and analgesics |
| 01/30/2003 | US20030022890 Heterocyclic dihydropyrimidine compounds |
| 01/30/2003 | US20030022885 Pyrazole compounds useful as protein kinase inhibitors |
| 01/30/2003 | US20030022883 Poly(adenosine 5'-diphospho-ribose) polymerase (PARP) inhibitors; compounds based on thieno(4,3,2-ef)(2)benzazepin-6-one |
| 01/30/2003 | US20030022836 Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules |
| 01/30/2003 | US20030022822 Novel compounds |
| 01/30/2003 | US20030022817 A protein hydrolysate to the preparation of a energy supplementation or metabolic nutrient, characterized in, that it is an animal or vegetable protein hydrolysate having a degree of hydrolysis of 1-50 |
| 01/30/2003 | US20030022338 Kunitz-type protease inhibitor polynucleotides, polypeptides, and antibodies |
| 01/30/2003 | US20030021755 Headache therapy |
| 01/30/2003 | US20030021754 Aerosols; vaporization, cooling |
| 01/30/2003 | US20030021753 Delivery of antiemetics through an inhalation route |
| 01/30/2003 | CA2454059A1 Substituted piperazine compounds and their use as fatty acid oxidation inhibitors |
| 01/30/2003 | CA2453967A1 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 01/30/2003 | CA2453965A1 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 01/30/2003 | CA2453636A1 Polypyrroles as agents for treating cancer, treating viral diseases and causing immunosuppression |
| 01/30/2003 | CA2453633A1 Aryl substituted thiazolidinones and the use thereof |
| 01/30/2003 | CA2452678A1 Combination of eplerenone and an hmg coa reductase inhibitor |
| 01/30/2003 | CA2450437A1 1-phenylsulphonyl-1,3-dihydro-2h-indol-2-one derivatives, their preparation and their therapeutic application |
| 01/29/2003 | EP1278869A2 Proteases |
| 01/29/2003 | EP1278846A2 Cytoskeleton-associated proteins |
| 01/29/2003 | EP1278827A2 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
| 01/29/2003 | EP1278770A1 Human wingless-like gene |
| 01/29/2003 | EP1278767A1 Albumin fusion proteins |
| 01/29/2003 | EP1278765A2 Immunodominant acetylcholine receptor alpha subunit peptides, complexes thereof with mhc class ii components and their use |
| 01/29/2003 | EP1278750A1 Imidazopyrimidine derivatives and triazolopyrimidine derivatives |
| 01/29/2003 | EP1278749A1 USE OF 5-THIO-, SULFINYL- AND SULFONYLPYRAZOLO 3,4-b]-PYRIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS |
| 01/29/2003 | EP1278748A2 Inhibitors of human phosphatidyl-inositol 3-kinase delta |
| 01/29/2003 | EP1278746A2 Dihydropyridine compounds and methods of use |
| 01/29/2003 | EP1278734A2 Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore |
| 01/29/2003 | EP1278732A1 1-aroyl-piperidinyl benzamidines |
| 01/29/2003 | EP1278730A2 4-benzyl-1- 2-(4-hydroxy-phenoxy)-ethyl]-piperidine-3,4-diol |
| 01/29/2003 | EP1278728A1 Pyrrolidine and piperidine derivatives and their use for the treatment of neurodegenerative disorders |
| 01/29/2003 | EP1278723A2 P-(sulfonyl)-aryl and -heteroaryl amines |
| 01/29/2003 | EP1278722A1 Aryl and heteroaryl sulfonates |
| 01/29/2003 | EP1278544A2 Albumin fusion proteins |
| 01/29/2003 | EP1278502A2 Protease inhibitors |
| 01/29/2003 | CN1100031C Cyclohexane derivatives |
| 01/28/2003 | US6511997 For treatment of a disease associated with tumor necrosis factor alpha, interleukin 1, interleukin 6 or cyclooxygenase II; such as irritable bowel disease |
| 01/28/2003 | US6511825 Cell signaling polypeptides and nucleic acids |
| 01/28/2003 | US6511685 Heating in presence of bacteria then yeast; adding calcium, magnesium and/or potassium components; filtering and drying |
| 01/23/2003 | WO2003006500A1 Method for obtaining a tgf-beta enriched protein fraction in activated form, protein fraction and therapeutic applications |
| 01/23/2003 | WO2003006467A1 Novel anticonvulsant derivative salts |
| 01/23/2003 | WO2003006045A2 Cxcl10 treatment of secondary tissue degeneration |
| 01/23/2003 | WO2003006010A1 Aerosol formulations of δ8 tetrahydrocannabinol |
| 01/23/2003 | WO2003006008A1 A method for treatment and/or prophylaxis |
| 01/23/2003 | WO2003005998A2 A pharmaceutical composition comprising a nicotinic receptor partial antagonist and an antiemetic agent of modulating cholinergic function |
| 01/23/2003 | WO2003005997A1 A composition for use in prophylaxis and/or treatment |
| 01/23/2003 | WO2002088143A3 Dihydroimidazo[4,5-e]indole and 7h-pyrrolo[3,2-f]quinoxaline derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands |
| 01/23/2003 | WO2002050066A3 Pyrazole compounds useful as protein kinase inhibitors |
| 01/23/2003 | WO2002036741A3 Polynucleotide encoding an activated human t-lymphocyte-derived protein related to ubiquitin conjugating enzyme |
| 01/23/2003 | WO2002024906A9 Induction of exon skipping in eukaryotic cells |
| 01/23/2003 | WO2002010363A3 Protein phosphatases |